Intermune plots another Phase III for pirfenidone

Intermune ($ITMN) says it will begin enrollment of another late-stage trial of idiopathic pulmonary fibrosis drug pirfenidone in the first half of 2011. Eight months ago, the FDA rejected the company's application for approval, noting that another trial would be necessary if the company ever hopes to sell the drug in the U.S. Intermune has seen success in Europe, however, where a panel of experts issued a positive opinion of the drug in late 2010. Report

Suggested Articles

The platform, which is in use at companies including Agios, enables researchers to simultaneously detect DNA and protein changes in single cells. 

As Urovant gears up for the launch of vibegron, its overactive bladder treatment, it is pushing the same drug through the clinic in other indications.

MicuRx nabbed $7.78 million from a nonprofit focused on antimicrobial resistance to push its third antimicrobial program into human trials.